What is Synchron?
Synchron is a pioneering neurotechnology enterprise dedicated to the development of minimally invasive brain-computer interfaces. Its flagship innovation, the Stentrode system, represents a significant leap in medical engineering, designed to facilitate hands-free digital control for individuals suffering from paralysis. By leveraging endovascular approaches, Synchron bypasses the need for traditional, high-risk open-brain surgery, positioning itself at the intersection of advanced neural decoding and accessible healthcare. The company's market position is bolstered by its ability to translate complex neural signals into actionable digital commands, effectively bridging the gap between biological intent and technological execution. As the industry shifts toward more integrated human-machine interfaces, Synchron remains a key player in defining the standards for next-generation neural prosthetics and therapeutic digital health solutions.
How much funding has Synchron raised?
Synchron has raised a total of $275M across 2 funding rounds:
Series C
$75M
Series D
$200M
Series C (2022): $75M with participation from Bezos Expeditions and ARCH Venture Partners
Series D (2025): $200M led by Bezos Expeditions, ARCH VENTURE PARTNERS, Double Point Ventures, and Khosla Ventures
Key Investors in Synchron
Bezos Expeditions
An investment firm founded by Jeff Bezos that focuses on a diverse range of sectors including technology, healthcare, and space exploration, known for backing transformative startups.
ARCH Venture Partners
A leading venture capital firm that specializes in creating and investing in life sciences and advanced technology companies, often co-founding startups to commercialize university-led innovations.
Double Point Ventures
A venture capital firm focused on innovative healthcare companies, providing strategic partnerships and expertise to accelerate growth in therapeutics, diagnostics, and digital health.
What's next for Synchron?
With the successful closure of this major enterprise-level funding, Synchron is well-positioned to accelerate its clinical trial roadmap and refine its neural decoding algorithms. The strategic focus will likely shift toward expanding the application of the Stentrode system beyond initial paralysis use cases, potentially exploring broader neurological conditions. By leveraging the expertise of its high-profile investor base, the company is expected to navigate the complex regulatory landscape of medical devices while scaling its manufacturing capabilities to meet future demand. This capital infusion provides the necessary runway to solidify its competitive moat in the rapidly evolving neuro-tech landscape, ensuring that Synchron remains at the forefront of innovation in human-machine integration.
See full Synchron company page
